ReviewFrontiers in oncology2026
Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Continuous efforts have been made to optimise treatment approaches for renal cell carcinoma (RCC), including locally advanced (la)RCC and metastatic (m)RCC. To update their joint consensus statements on the management of la/mRCC, the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology convened a series of Delphi meetings. Methods: A panel of six urologists and eight clinical oncologists was formed, addressing five areas: (i) surgical and (neo)adjuvant treatment in laRCC; (ii) first-line management of clear cell mRCC; (iii) second- and later-line treatment of clear cell mRCC; (iv) management of mRCCs with sarcomatoid features or non-clear cell histology; and (v) management of oligometastatic RCC. Consensus statements were drafted based on an extensive literature review and panel discussions. A consensus statement was established only if ≥ 80% of the panellists selected 'accept completely' or 'accept with some reservation' from a five-point Likert scale through anonymous voting. Results: A total of 42 consensus statements were accepted. Compared with the previous version, this set of consensus statements asserted the use of adjuvant therapy for laRCC and the use of immunotherapy-based combination therapy across different types of mRCC; multiple new areas were also added, including active surveillance in mRCC patients with very favourable prognosis, a novel therapeutic agent for mRCC (belzutifan), and the definitions and management of oligometastatic/oligoprogressive RCC. Conclusion: While several research gaps remain to be addressed, this set of consensus statements reflects contemporary approaches for la/mRCC management, offering practical references for clinicians in Hong Kong and the Asia-Pacific region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.